However, there has never been an in vivo experiment performed to reliably determine whether alectinib is a significant substrate for ABCB1/ABCG2, and there might be additional reasons why repotrectinib might be relatively more efficacious than alectinib, possibly evening out a more limited brain (tumor) penetration. This evidence concerns the gene ABCB1 and neoplasm.